JP2020512287A - 肺の炎症性疾患を処置するための方法 - Google Patents

肺の炎症性疾患を処置するための方法 Download PDF

Info

Publication number
JP2020512287A
JP2020512287A JP2019531167A JP2019531167A JP2020512287A JP 2020512287 A JP2020512287 A JP 2020512287A JP 2019531167 A JP2019531167 A JP 2019531167A JP 2019531167 A JP2019531167 A JP 2019531167A JP 2020512287 A JP2020512287 A JP 2020512287A
Authority
JP
Japan
Prior art keywords
asthma
defensin
defensins
hbd2
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019531167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512287A5 (https=
Inventor
ノードキルド，ペーター
クジャールフ，ソーレン
Original Assignee
ディフェンシン セラピューティクス エーピーエス
ディフェンシン セラピューティクス エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディフェンシン セラピューティクス エーピーエス, ディフェンシン セラピューティクス エーピーエス filed Critical ディフェンシン セラピューティクス エーピーエス
Publication of JP2020512287A publication Critical patent/JP2020512287A/ja
Priority to JP2024186110A priority Critical patent/JP2025013922A/ja
Publication of JP2020512287A5 publication Critical patent/JP2020512287A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019531167A 2016-12-13 2017-12-13 肺の炎症性疾患を処置するための方法 Ceased JP2020512287A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024186110A JP2025013922A (ja) 2016-12-13 2024-10-22 肺の炎症性疾患を処置するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670991 2016-12-13
DKPA201670991 2016-12-13
PCT/EP2017/082535 WO2018108971A2 (en) 2016-12-13 2017-12-13 Methods for treating inflammatory conditions of the lungs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024186110A Division JP2025013922A (ja) 2016-12-13 2024-10-22 肺の炎症性疾患を処置するための方法

Publications (2)

Publication Number Publication Date
JP2020512287A true JP2020512287A (ja) 2020-04-23
JP2020512287A5 JP2020512287A5 (https=) 2024-11-01

Family

ID=61024712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531167A Ceased JP2020512287A (ja) 2016-12-13 2017-12-13 肺の炎症性疾患を処置するための方法
JP2024186110A Withdrawn JP2025013922A (ja) 2016-12-13 2024-10-22 肺の炎症性疾患を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024186110A Withdrawn JP2025013922A (ja) 2016-12-13 2024-10-22 肺の炎症性疾患を処置するための方法

Country Status (13)

Country Link
US (2) US11413328B2 (https=)
EP (1) EP3554532B1 (https=)
JP (2) JP2020512287A (https=)
KR (1) KR20190108106A (https=)
CN (1) CN110290799A (https=)
AU (1) AU2017376400A1 (https=)
BR (1) BR112019011844A2 (https=)
CA (1) CA3045079A1 (https=)
ES (1) ES2994381T3 (https=)
MX (1) MX2019006848A (https=)
RU (1) RU2019120956A (https=)
SG (1) SG10202012106WA (https=)
WO (1) WO2018108971A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004863A (es) * 2017-11-10 2020-10-14 Defensin Therapeutics Aps Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro.
CN108815199B (zh) * 2018-08-03 2021-10-01 南华大学 鼠衣原体在制备抗溃疡性结肠炎药物中的应用
US11331269B2 (en) * 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
CN113164390A (zh) 2018-10-09 2021-07-23 达特·特兰 用于增强阳离子大环肽的全身递送能力、耐受性和效力的组合物和方法
JP7479381B2 (ja) * 2019-01-07 2024-05-08 アエスクルス バイオ エーピーエス 治療または予防に使用するためのディフェンシン断片
CA3132564A1 (en) * 2019-03-14 2020-09-17 Om Pharma Sa Process for making stable bacterial extracts and their use as pharmaceuticals
US12472231B2 (en) 2020-03-18 2025-11-18 The University Of Hong Kong Compositions of anti-viral peptides and methods of use thereof
CN113262297A (zh) * 2020-11-02 2021-08-17 中南大学湘雅二医院 一种基于巴氏菌的治疗性肺癌疫苗及其配置方法和应用
CN113521047B (zh) * 2021-08-23 2022-10-04 新疆医科大学第四附属医院 丁酸盐在制备慢性阻塞性肺疾病药物中的应用
CN118451094A (zh) * 2021-12-27 2024-08-06 港大科桥有限公司 抗病毒肽及其使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514060A (ja) * 2001-12-21 2005-05-19 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド アルブミン融合タンパク質
JP2011528332A (ja) * 2008-07-18 2011-11-17 ノボザイムス アデニウム バイオテック アクティーゼルスカブ 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
JP2015003920A (ja) * 2005-10-18 2015-01-08 メデラ セラピューティクス リミテッドＭｅｄｅｌｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ． 治療薬

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
WO2003070176A2 (en) 2002-02-19 2003-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Modified defensins and their use
CA2487895A1 (en) 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2008115390A2 (en) 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
SG172709A1 (en) 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
US8828380B2 (en) * 2009-09-10 2014-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the treatment of pulmonary disease and method of producing proteins of use therein
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
KR101329774B1 (ko) 2010-06-16 2013-11-15 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
US20130281361A1 (en) * 2010-11-08 2013-10-24 Pulmatrix, Inc. Methods of treating and preventing rhinovirus infection
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) * 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
US9464124B2 (en) * 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2653754C2 (ru) 2012-12-06 2018-05-14 Пин Фарма, Инк. Лечение воспалительных, аутоиммунных и нейродегенеративных нарушений иммуннодепрессивными полипетидами, являющимися производными тат
MX2020004863A (es) 2017-11-10 2020-10-14 Defensin Therapeutics Aps Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514060A (ja) * 2001-12-21 2005-05-19 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド アルブミン融合タンパク質
JP2015003920A (ja) * 2005-10-18 2015-01-08 メデラ セラピューティクス リミテッドＭｅｄｅｌｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ． 治療薬
JP2011528332A (ja) * 2008-07-18 2011-11-17 ノボザイムス アデニウム バイオテック アクティーゼルスカブ 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置

Also Published As

Publication number Publication date
AU2017376400A1 (en) 2019-06-20
RU2019120956A (ru) 2021-01-15
WO2018108971A3 (en) 2018-07-26
BR112019011844A2 (pt) 2022-05-10
KR20190108106A (ko) 2019-09-23
US20190336576A1 (en) 2019-11-07
CN110290799A (zh) 2019-09-27
EP3554532A2 (en) 2019-10-23
US20230067261A1 (en) 2023-03-02
ES2994381T3 (en) 2025-01-23
EP3554532C0 (en) 2024-09-25
EP3554532B1 (en) 2024-09-25
SG10202012106WA (en) 2021-01-28
JP2025013922A (ja) 2025-01-28
CA3045079A1 (en) 2018-06-21
MX2019006848A (es) 2019-10-07
WO2018108971A2 (en) 2018-06-21
RU2019120956A3 (https=) 2021-04-13
US11413328B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
US20230067261A1 (en) Methods for treating inflammatory conditions of the lungs
US20250009844A1 (en) Maturation of mucosal defense and gut/lung function in the preterm infant
JP6001151B2 (ja) 顆粒球マクロファージコロニー刺激因子を投与することによる肺の宿主防御の増強
Smaldone Repurposing of gamma interferon via inhalation delivery
JP4537956B2 (ja) 喘息治療剤
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
US20130281361A1 (en) Methods of treating and preventing rhinovirus infection
WO2014012559A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
US8697635B2 (en) Pharmaceutical preparation to be administered into respiratory organs for treating or preventing inflammatory respiratory diseases, and method for treating or preventing such diseases
WO2015110536A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220804

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220804

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220914

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221006

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221011

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221104

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241022

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250826